Compare Merck & Co., Inc. (MRK) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Exxon Mobil Corporation — how do they compare? Merck & Co., Inc. trades at $133.14 (market cap $321.77B), while Exxon Mobil Corporation trades at $159.36 (market cap $657.08B). The key difference: Exxon Mobil Corporation is far larger — about 2× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| MRK | XOM | |
|---|---|---|
Market Cap | $321.77B | $657.08B |
Sector | Health | Energy |
52-Week High | $131.84 | $171.52 |
52-Week Low | $77.60 | $106.13 |
Enterprise Value | $368.53B | $688.86B |
Dividend Yield | 2.61% | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue reached $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, supported by analyst consensus favoring a buy rating (67.57%) and a price target of $140.36. Key opportunities include pipeline expansion through M&A and solid cash flow generation. Risks involve high valuation multiples, such as a P/E of 104.34, and potential integration challenges from acquisitions. Investors should weigh growth prospects against elevated earnings expectations and market volatility.
ExxonMobil (XOM) trades at $159.79, up 4.48% today, showing strong momentum near its consensus price target of $163.71. The stock maintains a bullish technical outlook with support at $156 and resistance at $162. Recent earnings show mixed results with Q2 2026 missing expectations, but profitability remains solid with a 9.07% net margin and 12.55% ROE. The company benefits from high oil prices and strategic Permian Basin operations, though revenue has declined from $398.7B in 2022 to $323.9B in 2025.
XOM presents a balanced investment case with analyst consensus leaning toward Hold (51.85%). Upside potential exists from oil price strength and operational efficiency, but risks include volatile energy markets and declining revenue trends. The stock's current valuation at 20.57x P/E appears reasonable given stable dividends and strong cash flow generation. Institutional sentiment remains cautiously optimistic with price targets suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
